Lymphoma  >>  hydrocortisone  >>  Phase 2
Welcome,         Profile    Billing    Logout  

26 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
hydrocortisone / Generic mfg.
NCT00002552: Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma

Completed
2
40
US
filgrastim, sargramostim, carmustine, cyclophosphamide, cytarabine, etoposide, leucovorin calcium, methotrexate, perfosfamide, therapeutic hydrocortisone, allogeneic bone marrow transplantation, autologous bone marrow transplantation, in vitro-treated bone marrow transplantation, peripheral blood stem cell transplantation, syngeneic bone marrow transplantation, radiation therapy
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
09/01
10/03
NCT00002471: Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Completed
2
US
asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, methotrexate, methylprednisolone, therapeutic hydrocortisone, thiotepa, vincristine sulfate
Memorial Sloan Kettering Cancer Center
Leukemia, Lymphoma
01/03
01/03
NCT00002494: Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Completed
2
134
US
cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, mesna, methotrexate, prednisone, therapeutic hydrocortisone, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Leukemia, Lymphoma
03/04
01/06
NCT00002970: 506U78 in Treating Patients With Refractory Hematologic Cancer

Completed
2
148
US
nelarabine, 506U78, Arranon, GW506U78, methotrexate, amethopterin, Folex, methylaminopterin, Mexate, MTX, cytarabine, ARA-C, arabinofuranosylcytosine, arabinosylcytosine, Cytosar-U, cytosine arabinoside, therapeutic hydrocortisone, Aeroseb-HC, Barseb HC, Cetacort, Cort-Dome, Cortef
National Cancer Institute (NCI), Children's Cancer Group
Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia
01/05
 
NCT00482053: Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Terminated
2
3
US
Autologous hematopoietic stem cell transplantation (auto-HSCT), Autologous peripheral blood progenitor cell (PBPC) transplantation, Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Allogeneic peripheral blood progenitor cell (PBPC) transplantation, Total lymphoid irradiation (TLI), Rituximab, Rituxan, Mabthera, Carmustine, BCNU, BiCNU, Etoposide, Eposin, Etopophos, Vepesid, VP-16, Filgrastim, Granulocyte colony-stimulating factor (G-CSF, GCSF), Colony-stimulating factor 3 (CSF-3), Anti-thymocyte globulin (ATG), Cyclosporine, Cyclosporin, CSP, Mycophenolate mofetil (MMF), CellCept, Cyclophosphamide, Cytoxan, Neosar, Acetaminophen, Tylenol, Diphenhydramine, Benadryl, Hydrocortisone, Cortef, Methylprednisolone, Solu-Medrol
Stanford University
Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL), Malignant Lymphoma, Non-Hodgkin
05/10
05/10
NCT00392834: Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Checkmark P2 data in Burkitt's lymphoma
Dec 2011 - Dec 2011: P2 data in Burkitt's lymphoma
Completed
2
34
US
filgrastim, pegfilgrastim, rituximab, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, liposomal cytarabine, methotrexate, therapeutic hydrocortisone, vincristine sulfate
AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC
Lymphoma
07/11
07/13
NCT00133991: Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

Completed
2
23
US
Filgrastim, Neupogen, G-CSF, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Cy, CTX, HiCy, Cytarabine, Ara-C, Methotrexate, MTX, Prednisone, Deltasone, Hydrocortisone, Vincristine, Oncovin, Leucovorin, Folinic acid
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI)
Leukemia, Lymphoma
08/11
08/13
AALL07P1, NCT00873093: Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed
2
148
US, Canada, RoW
L-asparaginase, ASNase, Colaspase, Crasnitin, Elspar, L-ASP, doxorubicin hydrochloride, ADM, ADR, Adria, therapeutic hydrocortisone, Aeroseb-HC, Barseb HC, Cetacort, Cort-Dome, Cortef, vincristine sulfate, liposomal vincristine, Marqibo, vincristine liposomal, vincristine sulfate liposome injection, cytarabine, ARA-C, arabinofuranosylcytosine, arabinosylcytosine, Cytosar-U, cytosine arabinoside, prednisone, DeCortin, Deltra, bortezomib, LDP 341, MLN341, VELCADE, pegaspargase, L-asparaginase with polyethylene glycol, Oncaspar, PEG-ASP, PEG-L-asparaginase, methotrexate, amethopterin, Folex, methylaminopterin, Mexate, MTX, etoposide phosphate, ETOP, Etopophos, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, filgrastim, G-CSF, Neupogen, leucovorin calcium, CF, CFR, LV, laboratory biomarker analysis, High Dose MTX
National Cancer Institute (NCI)
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
09/14
09/14
NCT00481832: Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Terminated
2
50
US
Cyclophosphamide, Cytoxan, Neosar, BCNU, BiCNU, Carmustine, Etoposide, Eposin, Etopophos, VP-16, Filgrastim, Granulocyte colony-stimulating factor (G-CSF, GCSF), Colony-stimulating factor (CSF) 3, Antithymocyte globulin, ATG, Cyclosporine, cyclosporin, cyclosporin A, Mycophenolate mofetil, MMF, CellCep, Rituximab, Rituxan, MabThera, Autologous hematopoietic stem cell transplantation (auto-HSCT), Autologous peripheral blood progenitor cell (PBPC) transplantation, Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Allogeneic peripheral blood progenitor cell (PBPC) transplantation, Total lymphoid irradiation, TLI, CD34+ Cells, Solu-Medrol, Methylprednisolone
Stanford University
Lymphoma, Non-Hodgkin
10/14
03/17
2014-003031-19: This is a study to valuate the activity and feasibility of a new sequential chemoimmunotherapy program in patients with Diffuse Large B Cell Lymphoma and central nervous system involvement at diagnosis or relapse.

Ongoing
2
76
Europe
METROTREXATO, RITUXIMAB, CITARABINA, IFOSFAMIDE, CARBOPLATINO, ETOPOSIDE, TIOTEPA, BCNU, cytarabine liposome intrathecal, Solution for injection, Concentrate for solution for infusion, Injection, Solution for infusion, Powder for solution for injection, Powder for concentrate for solution for infusion, Powder for solution for infusion, Suspension for injection, methotrexate, Cytarabine, rituximab, Etoposide, carboplastin, hydrocortisone
IELSG (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP), International Extranodal Lymphoma Study Group, IELSG, Erasmus MC, NKI-AVL, LUMC
systemic diffuse large B-cell lymphoma with central nervous system involvement at diagnosis or relapse, systemic diffuse large B-cell lymphoma with central nervous system involvement at diagnosis or relapse, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT00352027: Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

Completed
2
81
US
Adriamycin®, Doxorubicin, Vinblastine, Velban®, Nitrogen Mustard, Mustargen®, Mechlorethamine Hydrochloride, Cyclophosphamide, Nitrogen Mustard Derivative, Vincristine, Bleomycin, Blenoxane®, Etoposide, VP-16, Vepesid®, Prednisone, Synthetic congener of hydrocortisone, G-CSF, Filgrastim, Neupogen®, Radiotherapy, Radiation therapy
St. Jude Children's Research Hospital
Hodgkin's Lymphoma
05/15
11/22
NCT02535806: Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Terminated
2
2
US
Velcade, Bortezomib, Methotrexate, Methotrexate / Hydrocortisone / Cytarabine, Dexamethasone, Mitoxantrone, Vincristine, Pegaspargase
Children's Mercy Hospital Kansas City, Millennium Pharmaceuticals, Inc.
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
05/17
05/17
NCT02518750: Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Terminated
2
3
US
Dexamethasone, Decadron®, Panobinostat, LBH589, Liposomal vincristine, Vincristine sulfate liposome injection, VSLI, Marqibo®, Mitoxantrone, Novantrone®, Peg-asparaginase, Peg-L-asparaginase, Pegaspargase, Oncaspar®, Bortezomib, Velcade, MLN341, LDP-341, Intrathecal Triples, ITMHA, Methotrexate/Hydrocortisone/Cytarabine, High-dose methotrexate, HDMTX, 6-Mercaptopurine, 6-MP, Purinethol®, High-dose cytarabine, Ara-C, Cytosar-U®, Nelarabine, Arranon®, Compound 506U78, Cyclophosphamide, Cytoxan®, Etoposide, VP-16, Vepesid®, Clofarabine, Clolar™, Clofarex
St. Jude Children's Research Hospital, Novartis Pharmaceuticals, Spectrum Pharmaceuticals, Inc
Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
03/18
03/18
NCT02329080: New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Active, not recruiting
2
76
Europe, RoW
Methotrexate, Rituximab, Cytarabine, Thiotepa, liposomial cytarabine, Etoposide, Ifosfamide, Carmustine, whole brain radiotherapy
International Extranodal Lymphoma Study Group (IELSG)
Diffuse Large B-cell Lymphoma
08/19
12/23
NHL16, NCT01451515: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Completed
2
23
US
Prednisone, Prednisolone, Vincristine, Oncovin®, Vincristine sulfate, Daunorubicin, Daunomycin, Cerubidine®, PEG-asparaginase, Pegaspargase, Oncaspar®, Erwinia asparaginase, Erwinase®, Doxorubicin, Adriamycin®, Cyclophosphamide, Cytoxan®, Cytarabine, Ara-C, Cytosar-U®, Thioguanine, Purine antimetabolite, Clofarabine, Cl-F-Ara-A, CAFdA, 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine, Clofarex, Clolar^TM, Methotrexate, MTX, High-dose methotrexate (HD-MTX), Mercaptopurine, 6-MP, Purinethol®, Dexamethasone, Decadron®, Hydrocortisone, Cortef®, Etoposide, VP-16, Vepesid®
St. Jude Children's Research Hospital, National University, Singapore
Lymphoblastic Lymphoma
05/21
05/22
NCT01700946: Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Completed
2
80
US
dexamethasone, Decadron(R), vincristine sulfate, Oncovin(R), rituximab, Rituxan(R), clofarabine, Clolar(TM), clofarex, cyclophosphamide, Cytoxan(R), etoposide, VP-16, Vepesid(R), aldesleukin, IL-2, interleukin-2, Proleukin (R), pegaspargase, PEG-ASP, Peg-L-asparaginase, PEG-asparaginase, Oncaspar(R), methotrexate, MTX, HDMTX, mercaptopurine, 6-MP, Purinethol(R), cytarabine, Ara-C, Cytosar-U(R), mitoxantrone, Novantrone(R), teniposide, VM-26, Vumon(R), vinblastine, Velban(R), natural killer cell infusion, NK cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone, Cortef, allogeneic hematopoietic stem cell transplantation, HSCT, CliniMACS, Cell Selection System
St. Jude Children's Research Hospital, Cookies for Kids' Cancer, Assisi Foundation
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma
07/21
07/21
NCT04479267: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Recruiting
2
49
US
Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione, 53-03-2, Adasone, Cortancyl, Dacortin, , Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Prednisolone, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, .delta.1-Hydrocortisone, 1,2-Dehydrohydrocortisone, 50-24-8, 9120, Adnisolone, Aprednislon, Capsoid, Cortalone, Cortisolone, Methylprednisolone, (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione, 6Alpha-Methylprednisolone, Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Rituximab, 174722-31-7, 687451, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, POLATUZUMAB VEDOTIN, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Cyclophosphamide, 1-bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin monohydrate, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, Doxorubicin Hydrochloride, 14-Hydroxydaunorubicin Hydrochloride, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements, Double Expressor Lymphoma, High-grade B-cell Lymphoma
11/25
11/26
NCT05049473: Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Recruiting
2
100
Europe
Rituximab, Methotrexate, Dexamethasone, Iphosphamid, Vincristine, Etoposide, Cytarabine, Cyclophosphamide, Doxorubicin, Vindesine, Hydrocortisone, Prednisone
PETHEMA Foundation, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Mature B-Cell Leukemia Burkitt Type, Burkitt Lymphoma (BL), Unclassifiable Lymphoma Between DCBL and BL
01/24
01/24
NCT06390319: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Not yet recruiting
2
145
US
Dexamethasone, Decadron, Hexadrol®, Vincristine, Vincristine Sulfate, Oncovin, Daunorubicin, Daunomycin, Calaspargase pegol, ASPARLAS, Dasatinib, Sprycel®, Venetoclax, Venclexta®, Bortezomib, Velcade®, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), IT MHA, Cyclophosphamide, Cytoxan®, Cytarabine, Ara-C, Cytosine arabinoside, Mercaptopurine, 6-MP, Nelarabine, Arranon, Atriance, Methotrexate, Trexall®, Thioguanine, 6-thioguanine, Tabloid®
St. Jude Children's Research Hospital, AbbVie
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
12/27
12/33
NCT00354107: Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

Terminated
1/2
5
US
monoclonal antibody SGN-30, SGN-30, therapeutic hydrocortisone, Aeroseb-HC, Barseb HC, Cetacort, Cort-Dome, Cortef, ifosfamide, Cyfos, Holoxan, IFF, IFX, IPP, carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, etoposide, EPEG, VP-16, VP-16-213, methotrexate, amethopterin, Folex, methylaminopterin, Mexate, MTX, cytarabine, ARA-C, arabinofuranosylcytosine, arabinosylcytosine, Cytosar-U, cytosine arabinoside, pharmacological study, pharmacological studies, laboratory biomarker analysis
National Cancer Institute (NCI)
Anaplastic Large Cell Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma
01/10
01/10
NCT00626626: Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation

Terminated
1/2
8
US
Clofar, Cyclophos, Alemtuzumab, CLOLAR, Clofar, Cyclophos,Alemtuzumab(Ph II), Clolar, Campath
Milton S. Hershey Medical Center
Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma
01/10
01/10
T2017-002, NCT03817320 / 2019-001947-28: PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Active, not recruiting
1/2
31
US, RoW
Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin, Methotrexate (IT), Triple IT (Methotrexate, Hydrocortisone, Cytarabine), Leucovorin
Therapeutic Advances in Childhood Leukemia Consortium, Takeda, Children's Hospital Los Angeles
ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
12/24
06/25
HEM-iSMART D, NCT05658640: HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

Recruiting
1/2
26
Europe
Trametinib, Dexamethasone, Cyclophosphamide, Cytarabine, Intrathecal chemotherapy
Princess Maxima Center for Pediatric Oncology, Innovative Therapies For Children with Cancer Consortium, IBFM, Fight Kids Cancer
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
04/29
04/29
HEM-iSMART A, NCT05740449: HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Withdrawn
1/2
26
Europe
Decitabine, Venetoclax, Navitoclax, intrathecal chemotherapy
Princess Maxima Center for Pediatric Oncology, Innovative Therapies For Children with Cancer Consortium, IBFM, Fight Kids Cancer
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
10/29
10/29
HEM-iSMART C, NCT05745714: HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Not yet recruiting
1/2
26
Europe
Ruxolitinib, Venetoclax, Dexamethasone, Cyclophosphamide, Cytarabine, intrathecal chemotherapy
Princess Maxima Center for Pediatric Oncology, Innovative Therapies For Children with Cancer Consortium, IBFM, Fight Kids Cancer
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
10/31
10/31
HEM-iSMART B, NCT05751044: HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Not yet recruiting
1/2
26
Europe
Dasatinib, Venetoclax, Dexamethasone, Cyclophosphamide, Cytarabine, intrathecal chemotherapy
Princess Maxima Center for Pediatric Oncology, Innovative Therapies For Children with Cancer Consortium, IBFM, Fight Kids Cancer
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
10/31
10/31

Download Options